Table 2.
Patient group | No. (%) of resistant isolates in PFGE clusters | No. (%) of nonclustered resistant isolates | ||||
---|---|---|---|---|---|---|
I | II | III | IV | V | ||
Treated with: | ||||||
Penicillin | 6 (85.7) | 34 (100) | 7 (100) | 2 (100) | 0 | 2 (40) |
Erythromycin | 7 (100) | 28 (82.4) | 6 (85.7) | 2 (100) | 0 | 0 |
Clindamycin | 0 | 1 (2.9) | 0 | 2 (100) | 0 | 1 (20) |
Teicoplanin | 2 (28.6) | 3 (8.8) | 1 (14.3) | 0 | 0 | 0 |
Vancomycin | 0 | 0 | 0 | 0 | 0 | 0 |
Oxacillin | 7 (100) | 34 (100) | 7 (100) | 2 (100) | 0 | 1 (20) |
mecA gene carrier | 7 (100) | 34 (100) | 7 (100) | 2 (100) | 2 (40) | 2 (40) |